<DOC>
	<DOCNO>NCT00205595</DOCNO>
	<brief_summary>This study use Positron Emission Tomography ( PET ) study normal distribution PET ligand ( R ) - [ 11C ] PK11195 . This ligand use study inflammation brain several brain disorder like Alzheimer 's disease traumatic brain injury .</brief_summary>
	<brief_title>Normal Binding R-11CPK11195 Human Subjects</brief_title>
	<detailed_description>At University Hospital Vrije Universiteit PET ligand PK11195 label carbon-11 , ( R ) - [ 11C ] PK11195 , use study microglia activation in-vivo patient traumatic brain damage , Alzheimer disease , multiple sclerosis neuritis optica , disorder unknown pathophysiology treatment difficulty . PK11195 ( 1- ( 2-chlorophenyl ) -N-methyl-N-1 ( 1-methylpropyl ) -3 isoquinolinecarboxamide ) highly specific ligand peripheral benzodiazepine-binding site , particularly abundant cell mononuclear macrophage line ( Myers et al. , 1991 ) . In normal human brain , peripheral-type benzodiazepine receptor ligand PK11195 exhibit low minimal bind primarily associate choroid plexus , ependymal lining glial cell . However , follow neuronal damage , cell involve ensue gliosis , microglia , show mark increase expression site ( Stephenson et al. , 1995 ; Conway et al. , 1998 ) . PK11195 label carbon-11 PET ligand peripheral type benzodiazepine receptor already use patient stroke ( Ramsay et al. , 1992 ) , Rasmussen 's encephalitis ( Banati et al. , 1999 ) , multiple sclerosis ( Banati et al. , 1997 ) facial nerve lesion ( Myers et al. , 1999 ) . However , tracer kinetic model quantification fully validate ( R ) - [ 11C ] PK11195 . In order use ( R ) - [ 11C ] PK11195 PET-imaging microglia activation use longitudinal monitoring disease progression , baseline level ligand uptake healthy control population require . This study aim measure ( R ) - [ 11C ] PK11195 uptake normal brain different age group develop method quantification specific binding ( R ) - [ 11C ] PK11195 . Because ( R ) - [ 11C ] PK11195 uptake depend regional bloodflow , ( R ) - [ 11C ] PK11195 scan precede cerebral bloodflow scan H215O . OBJECTIVES - Determine distribution ( R ) - [ 11C ] PK11195 normal brain - Develop method quantification specific binding ( R ) - [ 11C ] PK11195 - Determine metabolic profile ( R ) - [ 11C ] PK11195 healthy volunteer DESIGN OF THE STUDY Forty healthy subject recruit , 20 male 20 female . This open study . The study consist one PET scan , perform Department Nuclear Medicine &amp; PET research VU University Medical Centre .</detailed_description>
	<mesh_term>PK 11195</mesh_term>
	<criteria>Male female subject Good physical mental Health evaluate medical history , physical examination screen laboratory test ( see appendix 1 ) . Age 18 40 year ( 20 subject ) 40 80 year ( 20 subject ) . Mini Mental State score &gt; 27 Body Mass Index ( B.M.I . ) 20 25 . Written inform consent subject . Hb must &gt; 8 mmol \ liter time screen . Previous neurotrauma loss consciousness Any clinical significant abnormality clinical laboratory test , include drug screening , ECG abnormality . History hypertension Any subject receive investigational medication within 30 day prior start study , schedule receive investigational drug . History psychiatric neurological illness History psychiatric neurological illness firstdegree relatives History alcohol and/or drug abuse ( DSMIV criterion ) Current use medication Blood donation within 3 month scan day Claustrophobia Metal object around body ( brace , pacemaker , metal fragment ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>microglia</keyword>
	<keyword>PET</keyword>
	<keyword>PK11195</keyword>
</DOC>